Kineta Total Assets 2014-2024 | KANT

Kineta total assets from 2014 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
Kineta Annual Total Assets
(Millions of US $)
2023 $10
2022 $17
2021 $13
2020 $115
2019 $18
2018 $136
2017 $79
2016 $91
2015 $19
2014 $12
2013 $7
Kineta Quarterly Total Assets
(Millions of US $)
2024-06-30 $1
2024-03-31 $2
2023-12-31 $10
2023-09-30 $11
2023-06-30 $18
2023-03-31 $13
2022-12-31 $17
2022-09-30 $10
2022-06-30 $15
2022-03-31 $32
2021-12-31 $13
2021-09-30 $70
2021-06-30 $81
2021-03-31 $92
2020-12-31 $115
2020-09-30 $54
2020-06-30 $64
2020-03-31 $73
2019-12-31 $18
2019-09-30 $94
2019-06-30 $106
2019-03-31 $123
2018-12-31 $136
2018-09-30 $64
2018-06-30 $79
2018-03-31 $82
2017-12-31 $79
2017-09-30 $61
2017-06-30 $62
2017-03-31 $75
2016-12-31 $91
2016-09-30 $104
2016-06-30 $45
2016-03-31 $52
2015-12-31 $19
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $12
2013-12-31 $7
Sector Industry Market Cap Revenue
Medical MED-BIOMED/GENE $0.000B $0.005B
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
Stock Name Country Market Cap PE Ratio
Plum Acquisition I (VEEA) United States $0.124B 0.00
Pono Capital Two (SBC) United States $0.036B 0.00
ANEW Medical (KLTO) United States $0.014B 0.00
Tupperware Brands (TUPBQ) United States $0.003B 0.00